enGene Therapeutics Inc. (ENGN): Total Liabilities
$53.76M
As of 2025-10-31
$58.03M
As of 2026-07-31
+4.3%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-10-31 | $53.76M | +39.4% | 2025-12-22, Balance as of period end |
| 2024-10-31 | $38.56M | +166.4% | 2025-12-22, Balance as of period end |
| 2023-10-31 | $14.47M | -69.5% | 2024-12-19, Balance as of period end |
| 2022-10-31 | $47.41M | n/a | 2024-01-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $53.76M | +39.4% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $62.51M | -30.3% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $22.80M | +50.3% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $64.77M | -66.2% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $105.67M | -18.8% |
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $52.53M | +2.2% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $64.95M | +69.7% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $13.06M | -8.8% |
| Instil Bio, Inc. (TIL) | 2025-12-31 | $89.66M | -4.8% |
Compare ENGN, MGX, CMPX, IPSC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗